LeMaitre Vascular Inc (LMAT)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $1.76B
Last updated: Nov 17, 2026 at 4:15 PM ET
LeMaitre Vascular Inc (LMAT) Statistics
LeMaitre Vascular (LMAT) has a market cap of $1.76B and an enterprise value of $1.90B. Its trailing P/E of 27.7x is below its 10-year median of 41.2x.
Total Valuation
Enterprise value is 8.05% above the market cap, as debt exceeds cash.
| Market Cap | $1.76B |
|---|---|
| Enterprise Value | $1.90B |
| Latest price (Nov 17, 2026) | $76.10 |
Key Dates
The next earnings report is expected on Feb 23, 2027, covering the quarter ending Dec 31, 2026. The next ex-dividend date is Nov 19, 2026.
| Next Earnings Date | Feb 23, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Next Ex-Dividend Date | Nov 19, 2026 |
| Next Payment Date | Dec 3, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 6.5x and 4.0x. Its year-end P/E ranged from 29.6x to 47.5x from 2016 to 2025.
| P/E Ratio | 27.7x |
|---|---|
| Forward P/E | 26.6x |
| P/S Ratio | 6.5x |
| Forward P/S | 6.4x |
| P/B Ratio | 4.0x |
| P/TBV Ratio | 5.2x |
| P/FCF Ratio | 26.0x |
| P/OCF Ratio | 23.1x |
| PEG Ratio | 2.6 |
Enterprise Valuation
Counting debt and cash, the company is valued at 22.1x EBITDA and 28.1x free cash flow.
| EV / Earnings | 30.1x |
|---|---|
| EV / Sales | 7.1x |
| EV / EBITDA | 22.1x |
| EV / FCF | 28.1x |
Price Statistics
The stock is down 13.33% over 52 weeks and trades 6.25% below its 50-day average.
| Beta (1Y) | 0.60 |
|---|---|
| 52-Week Change | -13.33% |
| 1-Month Change | -7.54% |
| 3-Month Change | -8.99% |
| 6-Month Change | -24.48% |
| 5-Year Change | +55.62% |
| 10-Year Change | +286.53% |
| Total Return (1Y) | -12.25% |
| Total Return (3Y CAGR) | +13.66% |
| Total Return (5Y CAGR) | +9.08% |
| Return vs SPY (1Y) | -22.92% |
| Max Drawdown (1Y) | -34.81% |
| Max Drawdown (3Y) | -34.81% |
| Sharpe Ratio (1Y) | -0.26 |
| Correlation with SPY (1Y) | 0.17 |
| 50-Day Average | $81.17 |
| 200-Day Average | $93.86 |
| 52-Week Range | $76.60 to $117.37 |
| RSI (14 Days) | 38.3 |
| Average Volume (20 Days) | 286.99K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 14.60x current liabilities, and total debt is 0.39x shareholder equity.
| Current Ratio | 14.60x |
|---|---|
| Quick Ratio | 12.54x |
| Debt / Equity | 0.39x |
| Debt / EBITDA | 1.99x |
| Debt / FCF | 2.53x |
| Interest Coverage | 14.15x |
Returns and Efficiency
Return on invested capital is 9.47% over the last 12 months, against a 5-year average of 9.19%.
| Return on Equity (ROE) | 14.66% |
|---|---|
| Return on Assets (ROA) | 9.65% |
| Return on Invested Capital (ROIC) | 9.47% |
| ROE (5Y Average) | 11.22% |
| ROA (5Y Average) | 8.38% |
| ROIC (5Y Average) | 9.19% |
| Asset Turnover | 0.43x |
| Inventory Turnover | 1.06x |
| Receivables Turnover | 7.53x |
| Cash Conversion Cycle | 374 days |
Taxes
Income tax took 22.61% of pretax income over the last 12 months.
| Income Tax (TTM) | $18.50M |
|---|---|
| Effective Tax Rate | 22.61% |
Scores
LMAT has an Altman Z-Score of 6.77, in the safe zone above 2.99, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 6.77 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 7 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $269.36M over the last 12 months is up 11.83% from the 12 months before.
| Revenue | $269.36M |
|---|---|
| Revenue Growth (YoY) | +11.83% |
| Gross Profit | $194.06M |
| Operating Income | $74.70M |
| Pretax Income | $81.83M |
| Net Income | $63.34M |
| EBITDA | $85.28M |
| Reported EPS (TTM) | $2.75 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 65.87% of the $656.03M in total assets.
| Cash and Equivalents | $27.49M |
|---|---|
| Total Debt | $169.32M |
| Net Debt | $141.82M |
| Net Debt Per Share | $6.20 |
| Working Capital | $470.89M |
| Shareholder Equity | $432.13M |
| Book Value Per Share | $18.89 |
| Tangible Book Value | $336.89M |
| Tangible Book Per Share | $14.73 |
| Total Assets | $656.03M |
| Total Liabilities | $223.90M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $9.21M of capital spending, operating cash flow left $67.00M of free cash flow.
| Operating Cash Flow | $76.20M |
|---|---|
| Capital Expenditures | $9.21M |
| Free Cash Flow | $67.00M |
| FCF Per Share | $2.93 |
| Depreciation and Amortization | $11.67M |
| Dividends Paid | $21.68M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 27.73%, against a 5-year average of 22.03%.
| Gross Margin | 72.04% |
|---|---|
| Operating Margin | 27.73% |
| Pretax Margin | 30.38% |
| Net Margin | 23.51% |
| EBITDA Margin | 31.66% |
| FCF Margin | 24.87% |
| Gross Margin (5Y Average) | 67.27% |
| Operating Margin (5Y Average) | 22.03% |
| Net Margin (5Y Average) | 17.78% |
Growth
Revenue grew 15.58% a year over 3 years, and EPS 33.29% a year.
| Revenue Growth (3Y CAGR) | +15.58% |
|---|---|
| Revenue Growth (5Y CAGR) | +14.05% |
| EPS Growth (3Y CAGR) | +33.29% |
| EPS Growth (5Y CAGR) | +18.82% |
| FCF Growth (3Y CAGR) | +49.81% |
| FCF Growth (5Y CAGR) | +18.54% |
| Operating Income Growth (3Y CAGR) | +36.28% |
| Book Value Per Share Growth (2Y CAGR) | +13.65% |
| Tangible Book Per Share Growth (2Y CAGR) | +23.03% |
Dividends and Yields
LMAT pays out 28.51% of earnings as dividends.
| Dividend Per Share (Annual) | $1.00 |
|---|---|
| Dividend Yield | 1.31% |
| Payment Schedule | Quarterly |
| Dividend Growth (3Y CAGR) | +16.96% |
| Dividend Growth (5Y CAGR) | +16.05% |
| Payout Ratio | 28.51% |
| FCF Payout Ratio | 32.36% |
| Earnings Yield | 3.61% |
| FCF Yield | 3.85% |
| Buyback Yield | 0.10% |
| Shareholder Yield | 1.34% |
Peer Position
Against 9 similar companies, LMAT has the 4th highest P/E.
P/E RatioPeer median 20.7x
P/S RatioPeer median 3.1x
ROICPeer median 6.96%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +8.20%
Dividend YieldPeer median 0.00%
| P/E Ratio | 27.7x vs 20.7x median |
|---|---|
| P/S Ratio | 6.5x vs 3.1x median |
| ROIC | 9.47% vs 6.96% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +11.83% vs +8.20% median |
| Dividend Yield | 1.31% vs 0.00% median |
Analyst Forecast
Consensus estimates put revenue growth at 10.26% and EPS growth at 12.03% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +10.26% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +12.03% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About LMAT
What is LMAT's market cap?
LeMaitre Vascular has a market cap of $1.76B. Its enterprise value, which adds debt and subtracts cash, is $1.90B.
What is LMAT's P/E ratio?
LeMaitre Vascular has a trailing P/E ratio of 27.7x and a forward P/E of 26.6x.
How many shares of LMAT are outstanding?
LeMaitre Vascular has 22.87M shares outstanding. The count is up 0.93% from a year earlier.
Does LMAT pay a dividend?
Yes. LeMaitre Vascular pays $1.00 a share a year, a dividend yield of 1.31%.
How much debt does LMAT have?
LeMaitre Vascular has $169.32M of total debt and $27.49M of cash and equivalents, a net debt position of $141.82M.
LMAT pages: Overview, Dividends, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts